Ezolid 400 tablet: Each coated tablet contains Linezolid USP 400 mg.
Ezolid 600 tablet: Each coated tablet contains Linezolid USP 600 mg.
Ezolid 600 IV infusion: Each ml contains Linezolid USP 2 mg.
Ezolid is a preparation of Linezolid which is a synthetic antibacterial agent belonging to the oxazolidinones class, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross resistance between Linezolid and other classes of antibiotics is unlikely. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.
Route of administration : Ezolid tablets should be taken in oral route with or without food. Ezolid IV infusion should be administered by intravenous infusion over a period of 30 to 120 minutes.
Nosocomial pneumonia / Community-acquired pneumonia / Complicated skin and skin structure infections:
Pediatric (Birth through 11 years): 10 mg/kg orally or IV every 8 hours for 10 to 14 days
Adults & Adolescents (12 years and older): 600 mg orally or IV every 12 hours for 10 to 14 days
Vancomycin-resistant Enterococcus faecium infections:
Pediatric: 10 mg/kg orally or IV every 8 hours for 14 to 28 days
Adults & Adolescents: 600 mg orally or IV every 12 hours for 14 to 28 days
Uncomplicated skin and skin structure infections:
<5 years: 10 mg/kg orally every 8 hours; 5-11 years: 10 mg/kg orally every 12 hours
Adults: 400 mg orally every 12 hours; Adolescents: 600 mg orally every 12 hours (10 to 14 days)
Neonates <7 days: 10 mg/kg every 12 hours initially.
No dose adjustment necessary when switching from IV to oral administration. Hepatic impairment: No dose adjustment recommended for mild-to-moderate impairment.
Monoamine oxidase inhibitors, SSRIs, and SNRIs increase risk of fatal serotonin syndrome (avoid co-administration); pseudoephedrine and dopamine increase blood pressure response.
Linezolid is contraindicated in patients with hypersensitivity to linezolid or any other component of this product. It is also contraindicated in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.
Common: Diarrhea, vomiting, headache, nausea, anemia, taste alteration, eosinophilia.
Overdose
In the event of overdosage, supportive care is advised, with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination of linezolid.
Category C. Available data have not identified major birth defects; use during pregnancy only if benefit justifies fetal risk. Lactation: Present in breast milk; monitor infant for diarrhea and vomiting.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.